Judit Pich

Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis

Juan G. Abraldeṣ, Càndid Villanueva, Carles Aracil et al. · Gastroenterology · 2016 · 322 citations

Increases Survival, Hepatology, Variceal Rebleeding Does +4

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

Estebán Martínez, María Larrousse, Josep M. Llibre et al. · AIDS · 2010 · 191 citations

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

José Ramón Arribas, Pierre‐Marie Girard, Roland Landman et al. · The Lancet Infectious Diseases · 2015 · 142 citations · Full text

Hiv/aids Counselling, Human Retrovirus, Antiviral Drug Development +9

Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial

Elisa Pose, Laura Napoleone, Ahmed Adel Amin et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 135 citations · Full text

Drug Safety, Hepatology, Decompensated Cirrhosis +8

Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir

Estebán Martínez, Polyana Monteiro d’Albuquerque, Josep M. Llibre et al. · AIDS · 2012 · 123 citations · Full text